Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The active ingredient-free vehicle solution to DLQ01 is a placebo control formulation developed by Dermaliq Therapeutics for use in clinical trials evaluating DLQ01, a topical prostaglandin F2α analogue for androgenetic alopecia. It is formulated using the proprietary hyliQ® technology platform, which serves as the carrier system but contains no active pharmaceutical ingredient. In Phase 1b/2a studies, it serves as a comparator to assess the safety and efficacy of DLQ01 in men with male pattern baldness.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on active ingredient-free vehicle solution to DLQ01.